As part of the pilot Business Research and Innovation Initiative programme, Micropace has competitively joined 19 other recipients out of 180 applications to complete a feasibility study in a high priority challenge posed by the Australian government. The study will take place over 12 weeks and aims to boost Australian innovation via high tech solutions...
Micropace has again been recognised as a leading high-tech exporter for NSW by being nominated in the 2016 awards for the Health and Biotechnology category. “The Premier’s NSW Export Awards is an annual program which aims to recognise excellence in the export of goods and services by NSW business. The Awards acknowledge the important...
Micropace today announced the long-awaited release of its revolutionary SureTouch Software 4.0. This re-thinking of the classic EPS320 interface has been hailed by early users as a leap forward in ergonomics and usability for electrophysiological diagnostic stimulators and is based on over 14 years of global market feedback. “… so far the staff comments have...
Micropace has again been recognized as a premier exporter in the Australian medtech community, this time profiled in The Daily Telegraph. Micropace founder and MD Dr Michael Cejnar speaks with the Daily Telegraph
Micropace celebrated its total export revenues of $45 Million with being awarded the Premier’s NSW Export Award, Western Sydney, 2013. The prize was presented by Charbel Geagea of Kelly + Partners (holding), accepted by Richard Savoie, Dr Michael Cejnar and Ms Dai Phan of Micropace Ian Murray, Executive Chairman of the Export Council of Australia...
The Export Council of Australia has announced that Micropace is a Finalist in the 2013 Premier’s NSW Export Awards. The awards showcase the best and brightest exporters, who are making moves in new markets and expanding the export footprint of NSW. Micropace will be in attendence at the Award Ceremony on 16th October to hopefully...
Micropace reports nearly 100% year over year sales growth in China for EPS320 Family of products. Rapid market growth and largely increased gov’t healthcare funding seen to be accelerating this market, which Micropace is well-positioned to grow in.
Micropace successfully completes second year in FDA ISO13485 Pilot Program.
Micropace releases new extended European offerings including the NE (New Europe), BA (Baltic), and Iberian configurations. For details including the countries specified in each configuration, download a Micropace catalogue or contact us directly.
Saudi SFDA approves Micropace stimulators for sale in Saudi Arabia.